LongevityLeak

Condition Strategy

Non-Alcoholic Fatty Liver Disease (MASLD)

Reduce hepatic steatosis and prevent progression to fibrosis and cirrhosis

Evidence Level B

Evidence and Risk Labels

Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.

See full scoring guide

Guidance Summary

MASLD affects approximately 25% of adults globally. Weight loss of 7-10% reduces hepatic steatosis significantly. Supplements including berberine and silymarin show consistent liver enzyme improvement.

Top Interventions

  • caloric deficit (7-10% weight loss)
  • aerobic and resistance exercise
  • low-fructose dietary modification
  • berberine
  • silymarin

Monitoring Priorities

  • ALT, AST, GGT
  • liver ultrasound
  • CAP score (controlled attenuation parameter)
  • FIB-4 fibrosis score

Source Links